Annual Newsletter 2017

Download a copy here. Newsletter_Autumn_2017.pdf

Latest

Katie Yarrow and friends take on the Edinburgh Marathon Relay for CPT

On the 27th May CPT supporter Katie Yarrow along with a group of university friends, took on the Edinburgh Marathon Relay; running in teams from the heart of Edinburgh to the picturesque county of East Lothian to raise awareness and funds for Parkinson's research.
Type 2 Diabetes Linked to Higher Rate of Parkinson's

The study published in Neurology is the largest study to date on the link between the two conditions.
Giles Harrison's Sleep.Walk Challenge for CPT

CPT supporter Giles Harrison will be taking on the extreme challenge of walking for 72 hours, with little or no sleep around Richmond Park in Surrey hoping to raise awareness and funds for Parkinson's.
Astrocyte Conversion by Microglia is Neuroprotective in PD Models

Following the recent exenatide trial results, further studies of the potentially important disease-modifying role of GLP-1's in Parkinson's are taking place. This recent study examines neuroprotection...

Type 2 Diabetes Linked to Higher Rate of Parkinson's

The study published in Neurology is the largest study to date on the link between the two conditions.
Astrocyte Conversion by Microglia is Neuroprotective in PD Models

Following the recent exenatide trial results, further studies of the potentially important disease-modifying role of GLP-1's in Parkinson's are taking place. This recent study examines neuroprotection...
Vitamin B3 Might Have Beneficial Effects for Parkinson's

Recently researchers have provided very interesting evidence that a form of vitamin B3, called Nicotinamide Riboside, may have beneficial effects for Parkinson’s...
Webinar Discussion: 'Does Exenatide reduce non-motor symptoms in Parkinson’s disease?'

Rewatch the first of our new quarterly Parkinson’s webinar series in partnership with Journal of Parkinson’s Disease and Parkinson’s Movement here.
Axovant Announces Deal for Investigational Gene Therapy Treatment

Biotech company, Oxford BioMedica, has agreed on a deal with Axovant Sciences of the US to commercialise its gene therapy for Parkinson’s...
Exenatide - Effects on Non-Motor Symptoms: A Follow Up Analysis

Funded by CPT, the recent exenatide trial results have been analysed for non-motor responses with the conclusion that 'exenatide may exert independent effects on mood dysfunction'.
4 Feet 4 Paws 4 Parkinson's

On 4th June, Lyndsey Isaacs set off with close friend Hanya Chlala and Lyndsey's dog Indi, to walk 200 miles around the coast of Scotland in memory of her late husband, Tom Isaacs, President & Co-Founder of The Cure Parkinson’s Trust.
Anti-diabetic Drugs and Their Exciting Potential in Parkinson's

Metabolism and energy production in cells are the central links between type II diabetes and Parkinson’s, and common to both these conditions are mitochondrial dysfunction and insulin resistance...
From Genetics to Clinic

Evolving genetic discoveries in Parkinson's into trials for disease modifying treatments...
One Year On...

Co-founder of The Cure Parkinson's Trust, Tom Isaacs, died suddenly on May 31st 2017. One year on we remember Tom's vision and look to the future of the promising research that Tom was instrumental in bringing about.

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.
Trials - Repurposed drugs

Our Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop, or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Our story
Apply for Funding
The NAC Trial - the facts
Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
Science news

Read the latest Parkinson's science and research news here.
Stem Cell Therapies - Research Update

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.

Science news

Read the latest Parkinson's science and research news here. Read more

The Annual Review 2018

Our Annual Review 2018 - your online publication here... Read more

Alison Anderson - Fundraiser of the Year 2017

We are delighted that Alison Anderson is the Alex Flynn Award winner of 2017! Following her diagnosis with Parkinson's, Alison was determined to move forward with optimism - so she took on an awesome and inspiring challenge... Read more

Leave a gift in your Will

A donation to The Cure Parkinson's Trust will make a huge difference to our research to slow, stop or even reverse Parkinson's. Read more